There is a growing evidence that Artificial Intelligence and Machine Learning can improve small molecule drug discovery processes and, in particular, the compound design process. Augmentation with an AI component can lead to a reduced number of compounds tested in vitro (hence reduced cost and time), as well as to a diversification of the explored chemical space (hence higher likelihood of success). Thereby, we can optimize key stages of the compound design process: hit identification, hit to lead, and lead optimization. Here, we discuss the capabilities of our AI Platform for Compound Design with components for property/affinity prediction (with in silico validation) and molecule optimization. We provide examples of applications of our algorithms to a drug discovery project of our client (with in vitro validation): virtual screening, prioritization of molecules in the drug discovery pipeline, and molecule optimization.
To read full article, complete the form below.
February 25, 2019
Cracow Network Training “Agile Bioinformatics for Agile Science” February 3-8, 2019